Google's (GOOG +0.1%) sell-side PTs have been surging as shares continue trading above $900 following a torrent of I/O news. The I/O news demonstrates "Google remains one of the most innovative and forward thinking companies of this generation," gushes Topeka, which has raised its PT to $999. Baird's PT is now at $1,025, and Argus' at $1,065. In some respects, the mood resembles that surrounding Apple not too long ago. [View news story]
My thought exactly. What could possibly go wrong!!
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
In my experience reverse splits spook bio investors because they think it will be followed by a share offering. This is not a concern with (INO) because they issued more shares a couple of months ago. They now have enough cash to last several months.
Omeros Announces $16.2 Million Registered Direct Offering of Common Stock [View article]
(OMER) is one of the most undervalued bio stocks out there so it was no surprise that the secondary offering was placed at a premium to the current stock price.
Some analysts thinks this company should be worth well over $10 a share which is over twice the current market price.
4 Mid-Cap Dividend Stocks Yielding Over 6% [View article]
Hi Anthony. Enjoyed the article but has (CG) really got a yield of over 10%? According the the Seeking Alpha chart it would only appear to have a yield of 2%!
The cycle turns. Apple's (AAPL) price target is upped to $525 from $465 by Barclays' Ben Reitzes, who maintains his Buy on the stock. Reitzes is no doubt a fan of the capital return plan after he got onboard months ago with the Einhorn idea of significantly bumping the dividend/buyback without touching overseas cash. Shares +1% premarket. [View news story]
I'm sure they will do the 10 : 1 split when the stock hits $1,000 later this year! ;)
Uranium's Dirty Little Secret - Investors Take Note [View article]
Solid article thanks. I have been building a position in (UEC) for several months now in anticipation of the uranium recovery. Should be an interesting year!
Stocks continue to grind higher, the S&P 500 +0.9% and the Nasdaq +1.1%. Apple is again a leader in the market, +1.9% today, and up about 15% from two weeks ago. Notably not participating today are the big banks, but the insurers - MetLife and Prudential post-earnings, and AIG pre-earnings (reports after the bell) - are charging higher. [View news story]
Will probably keep running till next month's unveiling of ios7 and then go flat over the summer till the next catalyst move upwards in the fall.
Stem Cells: Invest At Your Own Peril [View article]
Interesting read. Thanks.
I look on (NBS) as one of the more interesting plays in the sector. I loaded up another 5,000 shares yesterday on the sell off.
Always very curious as to why investors should act in this way on a share offering in the bio sector. We saw it with (ATHX) last October and (INO) a couple of months ago. (ATHX) has more than doubled since its share issue and (INO) is showing signs of recovering nicely too.
Why Microsoft Stock Is Going Up Despite Windows 8 Going Down [View article]
Thank you sir. An interesting read.
Although I respect your point of view and you give some compelling arguements why (MSFT) has room to run I think that (AAPL) is the better play at the current time if it can keep the recovery up. Still much upside left whereas (MSFT) could well take a breather for a few months.
S&P 500 (SPY) futures +0.15% following yesterday's big rally here and especially across the pond. Europe tacks on more gains, the Stoxx 50 +0.4% as momentum continues to build for an ECB rate cut next week. Apple is lower by 0.75%, erasing gains in the 5% area after the earnings and its plan to take on debt to return cash to shareholders. Nasdaq 100 (QQQ) futures +0.2%. [View news story]
Funny how the after hours trading went pear shape just when it was announced that there would not be any new product catalysts till the fall.
Hopefully it will fall to $350 so that they can start buying back shares at rock bottom prices. It also allows people like me to load up to!
Full Report On MGT Capital With 5 Upcoming Catalysts [View article]
I agree that (MGT) could be a very lucrative play in the next few months. The next week is going to be particularly interesting.
Google's (GOOG +0.1%) sell-side PTs have been surging as shares continue trading above $900 following a torrent of I/O news. The I/O news demonstrates "Google remains one of the most innovative and forward thinking companies of this generation," gushes Topeka, which has raised its PT to $999. Baird's PT is now at $1,025, and Argus' at $1,065. In some respects, the mood resembles that surrounding Apple not too long ago. [View news story]
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
Looking For Opportunity - 5 Biotechs That Crashed [View article]
Omeros Announces $16.2 Million Registered Direct Offering of Common Stock [View article]
Some analysts thinks this company should be worth well over $10 a share which is over twice the current market price.
4 Mid-Cap Dividend Stocks Yielding Over 6% [View article]
The cycle turns. Apple's (AAPL) price target is upped to $525 from $465 by Barclays' Ben Reitzes, who maintains his Buy on the stock. Reitzes is no doubt a fan of the capital return plan after he got onboard months ago with the Einhorn idea of significantly bumping the dividend/buyback without touching overseas cash. Shares +1% premarket. [View news story]
Uranium's Dirty Little Secret - Investors Take Note [View article]
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance [View article]
(ATHX) is one of my hot stocks for the year. I keep adding to my holding on any dips.
Stocks continue to grind higher, the S&P 500 +0.9% and the Nasdaq +1.1%. Apple is again a leader in the market, +1.9% today, and up about 15% from two weeks ago. Notably not participating today are the big banks, but the insurers - MetLife and Prudential post-earnings, and AIG pre-earnings (reports after the bell) - are charging higher. [View news story]
Stem Cells: Invest At Your Own Peril [View article]
I look on (NBS) as one of the more interesting plays in the sector. I loaded up another 5,000 shares yesterday on the sell off.
Always very curious as to why investors should act in this way on a share offering in the bio sector. We saw it with (ATHX) last October and (INO) a couple of months ago. (ATHX) has more than doubled since its share issue and (INO) is showing signs of recovering nicely too.
Why Microsoft Stock Is Going Up Despite Windows 8 Going Down [View article]
Although I respect your point of view and you give some compelling arguements why (MSFT) has room to run I think that (AAPL) is the better play at the current time if it can keep the recovery up. Still much upside left whereas (MSFT) could well take a breather for a few months.
Apple: There And Back Again [View article]
http://bit.ly/11RwJaa
Let's hope so!
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
S&P 500 (SPY) futures +0.15% following yesterday's big rally here and especially across the pond. Europe tacks on more gains, the Stoxx 50 +0.4% as momentum continues to build for an ECB rate cut next week. Apple is lower by 0.75%, erasing gains in the 5% area after the earnings and its plan to take on debt to return cash to shareholders. Nasdaq 100 (QQQ) futures +0.2%. [View news story]
Hopefully it will fall to $350 so that they can start buying back shares at rock bottom prices. It also allows people like me to load up to!